India is soon likely to participate in the WHO's "solidarity trial" for developing potential drugs for COVID-19, officials said on Friday.
At a press briefing on coronavirus at 4 pm, Health Ministry Joint Secretary Lav Agarwal said 75 new cases of coronavirus and four deaths have been reported in the last 24 hours.
"We are soon likely to participate in the WHO solidarity trial for developing potential drugs for COVID-19. Earlier we did not do it because our numbers were small and our contribution would have looked minuscule," Raman R Gangakhedkar, Head of Epidemiology and Communicable diseases at ICMR, said.
Agarwal said that a PSU has been ordered to provide 10,000 ventilators while Bharat Electronics Limited (BEL) has been requested to purchase 30,000 additional ventilators in one-two months amidst a shortage of the machines in the country.
Punya Salila Srivastava, Joint Secretary in the Ministry of Home Affairs (MHA), said that states and union territories (UTs) have been requested to make arrangements for food, water and sanitation for migrant labourers. Hotels and rented accommodation should stay open and functional.
She, however, ruled out any plan to ferry stranded migrants from across cities or states, saying that the whole idea of a lockdown was to ensure no movement of people from their present places.
Agarwal also said that keeping in mind that hospital OPDs are being shut, the government has issued national telemedicine guidelines.
"This facilitates the process wherein doctors sitting at their homes can provide services to the patients. We urge and request citizens to take advantage of it and doctors to utilise this," he said.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)